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Abstract  
Human mitochondrial diseases, defined as the diseases due to a mitochondrial oxidative 
phosphorylation defect, represent a large group of very diverse diseases with respect to phenotype 
and genetic causes. They present with many unsolved issues, the comprehensive analysis of which 
is beyond the scope of this review. We here essentially focus on the mechanisms underlying the 
diversity of targeted tissues, which is an important component of the large panel of these diseases 
phenotypic expression. The reproducibility of genotype/phenotype expression, the presence of 
modifying factors, and the potential causes for the restricted pattern of tissular expression are 
reviewed.  
Special emphasis is made on heteroplasmy, a specific feature of mitochondrial diseases, defined as 
the coexistence within the cell of mutant and wild type mitochondrial DNA molecules. Its existence 
permits unequal segregation during mitoses of the mitochondrial DNA populations and 
consequently heterogeneous tissue distribution of the mutation load. The observed tissue 
distributions of recurrent human mitochondrial DNA deleterious mutations are diverse but 
reproducible for a given mutation demonstrating that the segregation is not a random process. Its 
extent and mechanisms remain essentially unknown despite recent advances obtained in animal 
models.  
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1. Introduction 
The definition of mitochondrial disease has long been debated and two main definitions still 
coexist: one restricts these diseases to those due to an alteration of the mitochondrial oxidative 
phosphorylation pathway (OXPHOS) [1] while the second one encompasses all the diseases due to 
the alteration of a mitochondrial component [2]. The second definition has at least two 
disadvantages with respect to the medical point of view. It puts together diseases with 
pathophysiological mechanisms that totally differ from those expected from an OXPHOS defect. 
Striking examples are the acute intoxication by ammonia due to OTC or CPS mutations or the 
defective cortisol and corticosterone biosynthesis due to CYP11B1 mutations. Conversely it 
excludes diseases due to the alteration of a non-mitochondrial component that induces an OXPHOS 
defect. A well known example of that situation is the MNGIE (MyoNeuroGastroIntestinal 
Encephalopathy) syndrome due to mutations of TYMP encoding a cytosolic thymidine 
phosphorylase whose defect induces depletion of the mitochondrial DNA (mtDNA). In this review 
addressing the medical relevance of unsolved issues related to mitochondrial diseases, we define 
these diseases as those due to an OXPHOS defect.  
Within that definition, mitochondrial diseases present with many unsolved issues such as the 
relative role of the diverse facets of the bioenergetic defect, the amplitude and potential 
compensation of the induced modification of reactive oxygen species metabolism and/or apoptosis 
balance, and the interplay between altered mitochondrial signaling and cellular compensatory 
responses. These aspects are most often addressed in cellular models, which may lack relevance as 
cultured cells essentially rely on glycolysis for the energy production. Because of their direct impact 
on diagnosis, prognosis and/or therapeutic approaches of mitochondrial diseases this review will 
focus on the mechanisms underlying the extreme phenotypic diversity of mitochondrial diseases, 
and especially heteroplasmy, i.e. the coexistence within the cell of mutant and wild type mtDNA 
molecules, which is frequent with deleterious mtDNA mutations.  
 
2. The extreme phenotypic diversity of mitochondrial diseases is related to the diversity of the 
deleterious consequences of the causal genetic alterations. 
Signs/symptoms encountered in mitochondrial diseases are extremely diverse (Table 1). They 
may affect any organ. Furthermore within an organ or tissue they may involve different target cells 
(for example proximal tubular cells or glomerules in kidney) and/or imply different mechanisms 
(for example permanent muscle weakness with TK2 mutations vs isolated intolerance to exercise 
with MT-CYB mutations or rapid progression to cirrhosis with DGUOK or BCS1L mutations vs 
recurrent accesses of liver insufficiency with full recovery with UQCRB mutations).  
That extreme phenotypic diversity appears essentially related to the diversity of the causes. 
Indeed specific mutations most often reproducibly give identical or similar phenotype. This is 
commonly observed with mutations of nuclear DNA genes such as TK2, TYMP or DGUOK [3]. It is 
also encountered with mtDNA mutations. The three most recurrent mtDNA alterations (large size 
unique deletion, m.3243A>G MELAS and m.8344A>G MERRF mutation) have now been found in 
hundreds of patients. Their phenotypes share several common points but they also have unique 
features that often permit their recognition and, most importantly, indicate that they induce, at least 
partly, different mechanisms. The presence of lipomas for example is only observed with the 
m.8344A>G mutations and not with any other mtDNA-encoded tRNA genes. Although there 
always are overlapping or border cases, these are the minority and are over-represented in the 
literature.  
Restricted tissue expression of the altered gene could explain part of the phenotypic diversity 
(see below). It cannot explain the diverse deleterious consequences within a same tissue. Our 
knowledge of the link between mutation and symptoms is clearly insufficient. Dissecting out that 
link requires on the one hand complete understanding of the symptoms, which may be very difficult 
when dealing with very complex organs such as brain, and comprehensive analysis of the mutation 
molecular and cellular consequences, which obviously can only be addressed in surrogate models, 
either cells derived from patients or genetically-modified animals.  
 3. The influence of modifying factors could be demonstrated in few instances 
Modifying factors have been proposed to explain part of the phenotypic diversity observed with 
mitochondrial diseases. They cannot be demonstrated without sufficient recurrence of identical 
mutations as different mutations of the same gene may have significantly different impact. Such 
recurrence is rare in mitochondrial diseases because of the large genetic heterogeneity of these 
diseases.  
The presence of modifying factors could however be demonstrated in diseases due to mutations 
of the POLG or TK2 nuclear genes and of the mtDNA-encoded ND1, ND4 and ND6 genes causing 
Leber Hereditary Optic Neuropathy (LHON). They were proposed to underlie the absence of 
symptoms despite the presence of the mutations in LHON [4] or to significantly modify the 
presentation in the case of POLG or TK2 [5, 6].  
The nature of these modifying factors would be essential to unravel as it would indicate the 
mechanisms allowing efficient modulation of the clinical consequences of the OXPHOS defect. The 
main candidate genetic modifiers have been the mtDNA haplogroup and nuclear genes encoding 
mtDNA replication factors [6, 7]. Despite longstanding and intensive efforts in the case of LHON 
the modifying nuclear genes have however remained elusive [8-10]. The influence of the mtDNA 
haplogroup has been repeatedly proposed but has remained a likely hypothesis in the absence of 
reliable functional assay [11, 12]. Only few attempts have been made to address the possible 
modulation of genetic OXPHOS defects. Among these it is interesting to note that several methods 
aiming at the increase of mtDNA expression through overexpression of translation factors [13] or 
induction of mitochondrial biogenesis [14, 15] has shown promising efficacy.  
 
4. Restricted tissue expression of an OXPHOS defect may have numerous potential causes 
The restricted tissue expression of mitochondrial diseases can be ascribed to, at least, two 
different mechanisms. The first one is the restricted tissue expression of nuclear genes either the 
gene whose defect causes the disease and/or the genes involved in the cellular responses to the 
OXPHOS defect; the second mechanism is specific for heteroplasmic mtDNA mutation whose 
proportion may be heterogeneous between tissues. That latter phenomenon will be discussed in a 
specific chapter as it is both highly relevant to diseases and raises numerous unsolved issues. 
Several genes responsible for a restricted pattern of symptoms are ubiquitously expressed. This 
is the case for example of TK2 whose mutations induce an essentially isolated severe myopathy or 
for GFM1 associated with hepatopathy. The steady-state expression of the gene in the target tissue 
does not seem to be a predictive factor of the tissue-specific expression of the disease. Indeed it was 
low in muscle for TK2 [16] but high in liver for GFM1 [17].  
Restricted expression of gene(s) involved in the pathway targeted by the causal defect has also 
been proposed to play a role in the disease tissue-specific expression [17]. In that case it is the lack 
of appropriate compensation by these genes that would explain tissue sensitivity to the causal defect. 
That hypothesis has been supported by the observation of phenotypic improvement upon 
overexpression of the genes [13]. It is however lacking demonstration in human patients.  
An alternative hypothesis for the restricted sensitivity of certain tissues to generalized defects is 
the presence of specific energy-demanding mechanisms within these tissues. That hypothesis has 
been proposed for the urinary loss of substrates normally actively reabsorbed in proximal tubules or 
the severe intolerance to exercise observed in several mitochondrial diseases. It could underlie the 
prominent neuronal dysfunction as ionic transport is together a highly energy-consuming process 
and the basis of neuronal life. However these diverse signs/symptoms do not directly correlate with 
the severity of the energy deprivation; in particular they can lack in apparently severe generalized 
OXPHOS defect. Our lack of knowledge of the expression of the diverse mitochondrial diseases in 
the different tissues greatly hampers further understanding of that issue.  
Quantitative expression of OXPHOS itself has been proposed to underlie the predominant 
neuromuscular expression of mitochondrial diseases, the understatement being that tissues with 
high OXPHOS levels must strictly depend on their aerobic metabolism. This cannot be a 
straightforward simple explanation as, for example, heart is extremely rich in OXPHOS complexes 
that represent up to 20% of its mitochondrial inner membrane proteins. Nevertheless several 
generalized OXPHOS defects, due for example to mutations in mtDNA-encoded complex I 
subunits, present with severe brain disease but no heart symptoms. The role of the different amount 
of respiratory complexes between tissues in the impact of an OXPHOS defect thus remains to be 
deciphered.  
In addition to the global amount of OXPHOS, the relative ratio between complexes can 
significantly vary between tissues. In human clinical practice, muscle, liver and cultured skin 
fibroblasts are the most frequently assayed tissues. Even within that limited number of tissues, the 
levels of maximal velocity of each complex but also to the relative ratio between complexes appear 
clearly different (Figure 1A). Animal models allow addressing these differences. Indeed, similarly 
to human tissues, mouse muscle presents with higher complex IV, similar complex I and lower 
complex II than mouse liver. The overall mitochondrial activities are however much higher in mice 
than in humans (Figure 1B). Analysis with western blot on post nuclear supernatants from different 
mouse tissues confirms that different tissues present with striking differences in the ratio between 
complexes (Figure 1C). Whether these different amounts and relative ratios have significant impact 
on the response to OXPHOS defect remains to be determined. 
 
5. Heteroplasmy has relevant consequences for human diseases  
Heteroplasmy is specific for mtDNA mutations. It has several highly relevant consequences for 
human diseases.  
5.1 Most deleterious mtDNA mutations only induce defects when present in a very high 
proportion 
Enzymatic defects and their ensuing symptoms only occur when the mutation reaches a 
threshold proportion, which depends both on the organ and nature of the mutation but is often very 
high (above 80%). Lowering even partially the mutation load could therefore significantly improve 
the phenotype. Several attempts have been done towards that direction either targeting the 
replication of the mutant mitochondrial DNA in cellular or animal models [18, 19] or selecting for 
cells with lower mutation load in cellular models and in patients [20-22]. Although establishing the 
proof of principle these attempts have yet too show their efficacy on a broader field. 
5.2 Mitotic segregation allows highly heterogeneous tissue distribution of heteroplasmic 
mutations 
5.2.1 Clinical observations 
The coexistence of the two mtDNA populations leaves open the possibility of their unequal 
segregation during mitoses. Blood carrying the deleterious “MELAS” mutation (m.3243A>G) has 
been shown to decrease its mutation load with age [23]. Conversely muscle seems to progressively 
increase with age its mutation load in patients with inherited mtDNA deletion [24] or point 
mutation [25]. Normal ageing is accompanied by the progressive accumulation of low proportions 
of mtDNA deletions and point mutations in post-mitotic tissues [26].  
Clonal expansion, equivalent to extreme segregation, of one of these mtDNA alterations has 
been shown to be at the basis of the observed OXPHOS defect in muscle [27, 28], colon [29] and 
brain [30]. These studies confirmed that the threshold mutation proportion, inducing OXPHOS 
defect, was very high, often close to homoplasmy. Even a modest modulation of segregation could 
therefore significantly modify the resulting phenotype [31].  
Clinical practice shows that unequal segregation with subsequent heterogeneous mutation load 
between tissues is frequent [32, 33]. The diverse mtDNA-encoded deleterious point mutations fall 
into two categories with respect to their tissue distribution with most mutations presenting with a 
heterogeneous tissue distribution and some with a homogeneous one (Figure 2A and 2B). Clinical 
practice also shows that the process is not random as recurrent mutations had highly reproducible 
pattern for a given mutation. This is exemplified with the most recurrent mtDNA-encoded tRNA 
mutations: “MELAS” (m.3243A>G) and “MERRF” (m.8244A>G) mutations that we have to-date 
identified in dozens of patients (Figure 2C). In our experience, these two mutations presented with 
completely different segregation behavior. The MERRF mutation did not appear actively segregated 
as its proportion was homogeneous in blood, buccal cells and urinary sediment in 27 independent 
patients (mutation load differences between blood and buccal cells or urinary sediment close to zero 
and p=0.251 when comparing the two differences). This contrasted strikingly with the MELAS 
mutation whose mutation load significantly decreased from urinary sediment to buccal cells and 
blood (p<0.001 for each pair-wise comparison). Even if there are rare outlier points, active 
segregation, specific for some mutations, is thus undergoing but we do not understand the 
mechanisms underlying that observation.  
5.2.2 Lessons from animal models 
Rare heteroplasmic animal models have been obtained and allow addressing the tissular 
segregation. The most well studied one carried two different normal mtDNA obtained by cytoplast 
transfer into one cell-embryo [34]. These two different normal mtDNA were found to be actively 
segregated for during the animal lifespan, in a non-random fashion as one genotype was favored in 
kidney and liver while the other one was favored in blood and spleen [35]. Using linkage analysis 
and crosses with distantly related mouse species, Battersby  et al found three potential loci 
controlling the tissular segregation [36] and, more recently, identified GIMAP3 as a gene 
controlling active mtDNA segregation in blood [37]. How this gene can influence the fate of a 
normal mtDNA still remains an open question. 
5.2.3. Clinical consequences of heterogeneous tissue distribution 
One consequence of the pattern of tissue repartition is that it has to be taken into account by the 
diagnosis protocols. In contrast to the investigations of nuclear genes, blood cannot be considered 
as representative for the whole individual. In theory diagnostic investigations should always be 
performed on samples from a tissue affected by the disease. Surrogate tissues are however often 
used instead of the target tissue, for example in patients with essentially brain symptoms. The 
potential risk is then to get false negative results, in particular in the presence of extreme 
segregation (Figure 2A, mutation m.10014G>A). The issue of tissue distribution is also highly 
relevant to prognosis, which depends on the mutation load in the different tissues, particularly in 
brain.  
5.3 Segregation of mutations through generations 
Segregation also occurs before birth and has been involved in the rapid return to homoplasmy of 
heteroplasmic mtDNA molecules through what was called the genetic bottleneck [38]. It can 
theoretically take place at any step from the differentiation of primordial germinal cells, through 
their maturation into mature ovule, fecundation and embryogenesis.  
5.3.1 Observations in humans 
The segregation pattern seems different during oogenesis and during embryogenesis [39]. There 
again the segregation pattern depended on the nature of the mutation as mutations such as the 
m.8993T>G in MT-ATP6 gene rapidly shifted towards homoplasmy [40] while the MELAS 
mutation seemed to follow a more random pattern [39].  
5.3.2 Lessons from animal models 
Animal models have been used to address the existence and mechanisms of the genetic 
bottleneck. Transmission of heteroplasmic normal genotypes has shown that the bottleneck was due 
to low mtDNA copy number in oogonia but also to preferential amplification of mtDNA 
subpopulations during folliculogenesis [41, 42].  
Transmission of the deleterious mutations created by an exonuclease deficient mtDNA 
polymerase gamma has shown strong purifying selection against the most deleterious mutations 
[43]. Intriguingly mice harboring low proportions of a deleterious MT-ND6 frame-shift mutation 
were shown to transmit less and less of the mutation in their successive progeny, which would 
implicate some on-going selection at the ovarian level [44].  
5.3.3 Clinical consequences of segregation through generations 
With regards to clinical practice, segregation through generations has direct relevance to genetic 
counseling and the feasibility of prenatal diagnosis. There are still numerous questions regarding 
the extent of post-natal segregation that may occur during a lifespan. Several children with low 
proportions of a deleterious mtDNA mutation have now been born after prenatal diagnosis [39]. 
Their long term follow up will be essential to carefully record. 
 
6. Conclusion 
The extreme phenotypic diversity of mitochondrial diseases represents a great challenge for the 
medical community. It obviously renders difficult the diagnosis of the diseases but, more 
importantly, it shows that the involved deleterious mechanisms may be very diverse. The nature of 
the genetic defect is clearly very important but the multiple aspects of the target tissues are most 
probably as important, including the cell dependence on specific energy-requiring pathways and its 
capacity to develop adequate compensatory responses.  
Heteroplasmy is only one aspect of that diversity. Understanding the mechanisms of segregation 
of heteroplasmic mtDNA mutations would be essential for the care of patients. At the diagnosis 
level it would allow choosing the samples avoiding false negative results; it would provide an 
insight on the potential evolution of the mutation load during the patients’ lifespan; it might open 
possibilities for heteroplasmy modulation.  
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Legends to figures 
Figure 1: Relative amount of respiratory complexes in different tissues from humans and 
mouse. 
A) Enzymatic activities taken from the results obtained in three different diagnostic centers using 
spectrophotometric analyses of patients who were deemed to be free of mitochondrial diseases [45];  
B) Data from mouse tissues assayed with the same protocols as human samples. For liver, muscle 
or striatum, activities were measured on post-nuclear supernatants of tissue homogenates, which do 
not permit reliable measurement of ATP synthase activity (complex V). For fibroblasts activities 
were measured on whole cells homogenates where the measurement of complex I is unreliable; I= 
rotenone sensitive NADH ubiquinone oxidoreductase, II=succinate ubiquinone oxidoreductase, 
III=antimycin sensitive ubiquinol cytochrome c oxidoreductase, IV=cytochrome c oxidase, 
CS=citrate synthase;  
C) Western blot analysis of post-nuclear supernatants of homogenates from mouse muscle 
(quadriceps), liver and brain using Mitoprofile antibodies containing a cocktail of monoclonal 
antibodies against subunit alpha of complex V (CV, MW=53 kDa), core 2 subunit of complex III 
(CIII, MW=47 kDa), SDHB subunit of complex II (CII, MW=30 kDa), MT6CO2 subunit of 
complex IV (CIV, MW=24 kDa) and NDUFB8 subunit of complex I (CI, MW=20 kDa). Loaded 
proteins were 20 and 10 µg for each tissue. 
Figure 2: Diverse patterns of the heteroplasmy tissue distribution of point mutations affecting 
mtDNA-encoded tRNA genes 
A) Most point mutations of the mtDNA-encoded tRNA genes present with a heterogeneous tissue 
distribution with muscle (M) having higher proportion than blood (Bl), buccal cells (Bu) or hair (H). 
Cells from the urinary sediment (U) often have relatively high mutation load (see m.3243A>G 
“MELAS” mutation). Rare patients present with extreme mutation segregation as shown with 
mutation m.10014G>A of glytRNA, which was almost homoplasmic in muscle but absent in all 
other tissues.  
B) In contrast some mutations of the mtDNA-encoded tRNA genes present with a homogeneous 
mutation load in every available tissue Blood (Bl), Urinary sediment (U), buccal cells (Bu), Hair 
(H), Muscle (M) or kidney (K). 
C) Recurrent mutations allow demonstrating the reproducibility of the pattern of tissue distribution 
for a given mutation. 
Boxplot of mutation load difference calculated by subtracting the mutation load in blood from that 
of buccal cells (Buccal cells-Blood, Bu-Bl) or from that of urinary sediment (Urinary sediment-
Blood, Ur-Bl) in 123 patients with the m.3243A>G mutation (“MELAS”) and in 27 patients with 
the m.8344A>G mutation (“MERRF”).  
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